Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $12.6M | $208M | $1.50M | $392K | $566K | $7.25M |
| Revenue growth | — | — | — | — | — | 1551.6% | -99.3% | -73.9% | 44.4% | 1181.3% |
| Operating income | -$22.5M | -$65.0M | -$52.9M | -$61.4M | -$81.4M | $124M | -$55.5M | -$59.3M | -$61.9M | -$42.4M |
| Operating margin | — | — | — | — | -645.4% | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Net income | -$22.4M | -$64.8M | -$52.0M | -$60.5M | -$81.0M | $123M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Net margin | — | — | — | — | -642.3% | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (diluted) | -$2.28 | -$3.35 | -$2.11 | — | -$1.39 | $1.76 | -$0.77 | -$0.74 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.8M | -$31.5M | -$45.6M | -$51.1M | -$51.6M | $119M | -$55.2M | -$45.8M | -$56.0M | -$38.3M |
| Capital expenditures | $30.4K | $38.9K | $33.9K | $57.2K | $127K | $184K | $1.22M | $40.0K | $71.0K | $0.00 |
| Free cash flow | -$17.8M | -$31.5M | -$45.6M | -$51.1M | -$51.7M | $118M | -$56.5M | -$45.8M | -$56.0M | -$38.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $51.9M | $87.1M | $36.5M | $41.9M | $72.0M | $188M | $44.9M | $27.0M | $26.3M | $13.2M |
| Total assets | $53.0M | $89.5M | $47.6M | $80.8M | $75.9M | $195M | $155M | $144M | $92.2M | $151M |
| Total liabilities | — | — | $8.84M | $10.8M | $32.3M | $14.8M | $23.0M | $56.2M | $23.9M | $20.3M |
| Shareholders' equity | $49.3M | $83.4M | $38.8M | $70.0M | $43.6M | $180M | $132M | $87.8M | $68.2M | $131M |
| Retained earnings | -$35.9M | -$101M | -$153M | -$213M | -$294M | -$171M | -$226M | -$278M | -$304M | -$322M |
| Shares (wtd avg diluted) | 9.84M | 24.6M | 24.7M | 54.7M | 65.7M | 70.4M | 70.5M | 70.7M | 71.0M | 130M |
Every figure is extracted from Ovid Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.